www.chinaservicesinfo.com

News

Healthy authorities approve use of cholesterol drug

Updated: Aug 24, 2023 chinadaily.com.cn Print
Share - WeChat

China's National Medical Products Administration on Tuesday approved the use of Inclisiran, a cholesterol-lowering small interfering RNA (siRNA), for the treatment of adults with primary hypercholesterolemia (heterozygous familial and non-familial) or mixed dyslipidemia.

Developed by Novartis, Inclisiran is the world's only siRNA medicine for LDL-C reduction and will help make long-term lipid management easier for physicians and patients, said the company.

The European Medicines Agency had in December 2020 approved Inclisiran for use in the treatment of adults with primary hypercholesterolemia or mixed dyslipidemia. The US Food and Drug Administration approved it in December 2021 and expanded its indications to primary hypercholesterolemia patients in July 2023.

Copyright©2024 China Daily. All rights reserved.

京ICP备13028878号-6

京公网安备 11010502032503号 京公网安备 11010502032503号